FATE
Fate Therapeutics Inc
NASDAQ: FATE · HEALTHCARE · BIOTECHNOLOGY
$1.25
+0.81% today
Updated 2026-04-30
Market cap
$154.63M
P/E ratio
—
P/S ratio
23.27x
EPS (TTM)
$-1.15
Dividend yield
—
52W range
$1 – $2
Volume
1.4M
Fate Therapeutics Inc (FATE) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-12.14M | $-13.27M | $-15.37M | $-22.42M | $-18.40M | $-29.82M | $-36.91M | $-38.65M | $-83.17M | $-39.23M | $-162.87M | $-248.21M | $-132.26M | $-122.87M | $-106.08M |
| Capital expenditures | $2000.00 | $709000.00 | $244000.00 | $882000.00 | $1.50M | $457000.00 | $1.73M | $2.30M | $7.39M | $4.93M | $50.70M | $35.57M | $6.15M | $730000.00 | $5.95M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $172000.00 | $155000.00 | $1.55M | $2.43M | $2.40M | $3.18M | $3.61M | $6.29M | $17.41M | $30.75M | $54.36M | $78.73M | $43.46M | $41.50M | $24.92M |
| Free cash flow | $-12.15M | $-13.98M | $-15.62M | $-23.30M | $-19.89M | $-30.28M | $-38.63M | $-40.95M | $-90.57M | $-44.16M | $-213.57M | $-283.77M | $-138.42M | $-123.60M | $-112.04M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | $4.40M | — | $0.00 | $0.00 | $420000.00 | $186000.00 | $15.21M | — | $2.52M | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $44.95M | $-4.93M | $15.71M | $23.80M | $343000.00 | $101.67M | $-90.70M | $82.53M | $-33.76M | — | — | — | — |